zffoto / Shutterstock.com
A US advisory panel has reportedly approved the use of the CRISPR/Cas9 gene-editing technology on humans for the first time, as part of a study designed to target three types of cancer.
You need a subscription to continue reading this content.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
CRISPR, cancer, US advisory panel, FDA, human trial
